flow trial semaglutide kidney outcomes hazard ratio 0.76

flow trial semaglutide kidney outcomes hazard ratio 0.76 Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine FLOW trial Ozempic® (semaglutide injection)

Name: flow trial semaglutide kidney outcomes hazard ratio 0.76 Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine FLOW trial Ozempic® (semaglutide injection)
Brand: actil.am
SKU: 10145833645
Price: 27.01 USD
Availability: InStock
Rating: 4.6723 (6 reviews)

SKU: 10145833645

4.7

USD27.01 USD54.01

Pay in 4 interest-free payments of $6.75 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 14 - Aug 19

Description

Ueda and colleagues ran a nationwide Swedish register-based cohort (20132024), comparing initiators of GLP-1 receptor agonists (~107,500) against initiators of SGLT-2 inhibitors (~186,000)